{"id":"NCT03292484","sponsor":"Aimmune Therapeutics, Inc.","briefTitle":"Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008)","officialTitle":"A Multicenter, Open-Label, Longer-Term Study of AR101 Characterized Oral Desensitization Immunotherapy in Subjects Who Participated in a Prior AR101 Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-11-02","primaryCompletion":"2023-04-27","completion":"2023-04-27","firstPosted":"2017-09-25","resultsPosted":"2024-12-19","lastUpdate":"2024-12-19"},"enrollment":911,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Peanut Allergy"],"interventions":[{"type":"BIOLOGICAL","name":"AR101","otherNames":[]}],"arms":[{"label":"AR101","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to assess AR101's safety, tolerability and efficacy over an extended dosing period.","primaryOutcome":{"measure":"Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)","timeFrame":"From first dose of study drug through 30 days after last dose of study drug, up to 59 months","effectByArm":[{"arm":"AR101","deltaMin":866,"sd":null}],"pValues":[]},"eligibility":{"minAge":"1 Year","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":93,"countries":["United States","Canada","France","Germany","Ireland","Italy","Netherlands","Spain","Sweden","United Kingdom"]},"refs":{"pmids":["34389504","34320250"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":42,"n":908},"commonTop":["Cough","Vomiting","Pyrexia","Abdominal pain","Urticaria"]}}